Seeking Alpha
17 Nov 2026, 17:52 UTC · 9h ago
Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript
Impact · against what's priced in
Acadia's update is fundamentally positive but contains little catalyst for a price move as the key drivers—DAYBUE growth and patent extension—are already reflected in current valuations. The raised revenue guidance and substantial cash position provide stability but do not shift the long-term growth trajectory.
- ACAD+0.20
No priced-in read yet





